Patents Assigned to MIDWESTERN UNIVERSITY
-
Patent number: 11897857Abstract: Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) ?-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.Type: GrantFiled: December 11, 2020Date of Patent: February 13, 2024Assignee: Midwestern UniversityInventors: Mark Jon Olsen, Jean Paul Seerden
-
Patent number: 11236178Abstract: Monoclonal antibodies (MAbs) targeting one or more specific epitopes of aspartyl (asparaginyl) ?-hydroxylase (ASPH), including humanized, bi-specific, and other chimeric MAb variants, and fragments thereof (collectively ASPH epitope-specific MAbs, or simply ASPH MAbs), are disclosed. Methods of production, purification, and use of the ASPH epitope-specific MAbs, and compositions comprising them, as agents in therapeutic and diagnostic applications to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are also disclosed. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases.Type: GrantFiled: September 29, 2020Date of Patent: February 1, 2022Assignee: Midwestern UniversityInventor: Mark Jon Olsen
-
Patent number: 10961320Abstract: Monoclonal antibodies (MAbs) targeting one or more specific epitopes of aspartyl (asparaginyl) ?-hydroxylase (ASPH), including humanized, bi-specific and other chimeric MAb variants, and fragments thereof (collectively ASPH epitope-specific MAbs, or simply ASPH MAbs), are disclosed. Methods of production, purification, and use of the ASPH epitope-specific MAbs, and compositions comprising them, as agents in therapeutic and diagnostic applications to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are also disclosed. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases.Type: GrantFiled: June 18, 2019Date of Patent: March 30, 2021Assignee: MIDWESTERN UNIVERSITYInventor: Mark Jon Olsen
-
Patent number: 10961211Abstract: Isotopically-stabilized tetronimide compounds comprising one or more deuterium atoms, derivatives, and intermediates, thereof, including methods for their synthesis, pharmaceutical compositions thereof, and methods of using these compounds to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are disclosed. One aspect relates to molecules that modulate the expression or catalytic activity of aspartyl (asparaginyl) ?-hydroxylase (ASPH) within or on the surface of a cell. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases. Related aspects include uses of the compounds to modulate the activity of viruses, as anti-hyperlipidemia agents, and as agents to ameliorate or treat thrombosis and related cardiovascular and metabolic disorders.Type: GrantFiled: February 14, 2020Date of Patent: March 30, 2021Assignee: Midwestern UniversityInventors: Mark Jon Olsen, Jean Paul Seerden
-
Patent number: 10828368Abstract: Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.Type: GrantFiled: September 25, 2017Date of Patent: November 10, 2020Assignee: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Patent number: 10787445Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.Type: GrantFiled: June 12, 2019Date of Patent: September 29, 2020Assignee: Midwestern UniversityInventors: Mark Jon Olsen, John-Michael Thomas
-
Patent number: 10710995Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.Type: GrantFiled: September 26, 2017Date of Patent: July 14, 2020Assignees: Rhode Island Hospital, Midwestern UniversityInventors: Jack R. Wands, Suzanne De La Monte, Arihiro Aihara, Mark Jon Olsen, John-Michael Thomas
-
Patent number: 10688195Abstract: Provided herein are antibiotic coated nanoparticles and methods of treating bacterial infection therewith. In particular embodiments, polymyxin B, vancomycin, and/or other antibiotics are linked to nanoparticles (e.g., gold or silica nanoparticles) and utilized for the treatment of bacterial infections.Type: GrantFiled: March 17, 2017Date of Patent: June 23, 2020Assignees: NORTHWESTERN UNIVERSITY, MIDWESTERN UNIVERSITYInventors: Alan R. Hauser, Andrew Lee, Marc H. Scheetz, Nathaniel J. Rhodes
-
Patent number: 10561704Abstract: The present invention relates to compositions and methods for treating neuropsychiatric disorders in vertebrates and humans. More specifically, the present invention provides for use of IRL-1620, an endothelin-B receptor agonist, in appropriate doses to be a neuroprotective and a neuroregenerative agent. Accordingly, in one aspect the disclosure provides a method of treating a neuropsychiatric disorder comprising administering to a patient in need thereof a therapeutically effective amount of an endothelin-B receptor agonist to treat the neuropsychiatric disorder. In some embodiments, the endothelin-B receptor agonist is co-administered with an additional agent to treat the neuropsychiatric disorder. In some embodiments, the additional agent is selected from the group consisting of an antidepressant, an anti-inflammatory agent, a CNS stimulant, a neuroleptic, and an anti-proliferative agent.Type: GrantFiled: July 8, 2014Date of Patent: February 18, 2020Assignee: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Patent number: 10351555Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.Type: GrantFiled: September 14, 2018Date of Patent: July 16, 2019Assignee: Midwestern UniversityInventors: Mark Jon Olsen, John Michael Thomas
-
Patent number: 10112981Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: GrantFiled: November 15, 2016Date of Patent: October 30, 2018Assignee: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Patent number: 10106532Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.Type: GrantFiled: July 17, 2017Date of Patent: October 23, 2018Assignee: Midwestern UniversityInventors: Mark Jon Olsen, John Michael Thomas
-
Patent number: 9771356Abstract: The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) ?-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.Type: GrantFiled: September 20, 2013Date of Patent: September 26, 2017Assignees: Rhode Island Hospital, Midwestern UniversityInventors: Jack R. Wands, Suzanne De La Monte, Arihiro Aihara, Mark Jon Olsen, John-Michael Thomas
-
Patent number: 9493524Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: GrantFiled: January 7, 2014Date of Patent: November 15, 2016Assignee: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Patent number: 9339039Abstract: Disclosed are biocontrol agents for the control of insects (e.g., moths, and mosquitoes such as Aedes aegypti), in particular Chromobacterium vaccinii strains capable of killing insects such as mosquitoes and moths. More specifically, disclosed are Chromobacterium vaccinii strains MWU205 (NRRL B-50840), MWU300 (NRRL B-50841) and MWU328 (NRRL B-50842). Also disclosed is a biocontrol strategy whereby insects (e.g. mosquitoes, moths) are exposed to the Chromobacterium vaccinii strains MWU205, MWU300 or MWU328 as a method for killing insects, including insect larvae in more than one taxonomic order.Type: GrantFiled: July 23, 2014Date of Patent: May 17, 2016Assignee: The United States of America, as Represented by Midwestern UniversityInventors: Phyllis A. Martin, Scott Soby
-
Patent number: 8980874Abstract: Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.Type: GrantFiled: April 30, 2010Date of Patent: March 17, 2015Assignee: Midwestern UniversityInventor: Anil Gulati
-
Publication number: 20140193393Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: MIDWESTERN UNIVERSITYInventor: ANIL GULATI
-
Patent number: 8623823Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: GrantFiled: August 19, 2008Date of Patent: January 7, 2014Assignee: Midwestern UniversityInventor: Anil Gulati
-
Publication number: 20120093798Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: August 19, 2008Publication date: April 19, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati
-
Publication number: 20120083447Abstract: Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.Type: ApplicationFiled: April 29, 2010Publication date: April 5, 2012Applicant: MIDWESTERN UNIVERSITYInventor: Anil Gulati